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BACKGROUND
Scabies is an underrecognized cause of illness in many developing countries. It is as-
sociated with impetigo, which can lead to serious systemic complications. We con-
ducted a trial of mass drug administration for scabies control in Fiji.
METHODS
We randomly assigned three island communities to one of three different interventions 
for scabies control: standard care involving the administration of permethrin to af-
fected persons and their contacts (standard-care group), mass administration of per-
methrin (permethrin group), or mass administration of ivermectin (ivermectin group). 
The primary outcome was the change in the prevalence of scabies and of impetigo from 
baseline to 12 months.
RESULTS
A total of 2051 participants were enrolled; 803 were in the standard-care group, 532 in 
the permethrin group, and 716 in the ivermectin group. From baseline to 12 months, 
the prevalence of scabies declined significantly in all groups, with the greatest reduc-
tion seen in the ivermectin group. The prevalence declined from 36.6% to 18.8% in the 
standard-care group (relative reduction in prevalence, 49%; 95% confidence interval 
[CI], 37 to 60), from 41.7% to 15.8% in the permethrin group (relative reduction, 62%; 
95% CI, 49 to 75), and from 32.1% to 1.9% in the ivermectin group (relative reduction, 
94%; 95% CI, 83 to 100). The prevalence of impetigo also declined in all groups, with 
the greatest reduction seen in the ivermectin group. The prevalence declined from 
21.4% to 14.6% in the standard-care group (relative reduction, 32%; 95% CI, 14 to 50), 
from 24.6% to 11.4% in the permethrin group (relative reduction, 54%; 95% CI, 35 to 
73), and from 24.6% to 8.0% in the ivermectin group (relative reduction, 67%; 95% CI, 
52 to 83). Adverse events were mild and were reported more frequently in the ivermec-
tin group than in the permethrin group (15.6% vs. 6.8%).
CONCLUSIONS
Mass drug administration, particularly the administration of ivermectin, was effica-
cious for the control of scabies and impetigo. (Funded by the Australian National 
Health and Medical Research Council; Australian New Zealand Clinical Trials Registry 
number, ACTRN12613000474752.)
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Scabies, a skin condition that is rec-ognized by the World Health Organization as a disease of public health importance,1 is 
a substantial contributor to global morbidity and 
mortality. Scabies is caused by a microscopic mite 
(Sarcoptes scabiei var. hominis) and is transmitted 
primarily through person-to-person contact. In-
festation can result in debilitating itchiness, 
with associated sleep disturbance, reduced ability 
to concentrate,2 social stigmatization,3 and ongo-
ing health care expenses.4,5
In many developing countries, scabies-related 
scratching is an important cause of impetigo,6-10 
which is most often due to Streptococcus pyogenes 
or Staphylococcus aureus infection and can lead to 
septicemia, glomerulonephritis, and rheumatic 
heart disease.11 An estimated 100 million persons 
have scabies worldwide; most live in tropical 
countries,12 and those living in the Pacific Islands 
are particularly affected.10,13-16
Effective treatments, both topical and oral, are 
available for scabies. However, among persons 
who live in regions where the pathogen is en-
demic, reinfestation can occur rapidly, even when 
household contacts are also treated.17 Mass drug 
administration, which generally involves repeat 
administration of single-dose therapeutic agents 
to whole communities, has become a central 
strategy for the control of several neglected 
tropical diseases.1,18 Single-group studies of the 
mass administration of topical permethrin6,8 
and ivermectin (an oral agent that is the drug of 
choice for mass administration for onchocer-
ciasis and lymphatic filariasis)7,19-24 have shown 
promise. To strengthen the evidence base for 
mass drug administration for scabies control, 
we undertook a comparative trial called the Skin 
Health Intervention Fiji Trial (SHIFT).
Me thods
Study Population
We conducted SHIFT in Fiji from September 2012 
through September 2013. After consultation with 
health authorities, we identified three island 
communities as study groups (Fig. 1), on the 
basis of relative isolation, population size (small 
enough to be manageable but large enough to 
provide study power), and cultural similarities.25 
One community occupies a single island, the 
second occupies two neighboring islands, and 
the third occupies three islands. Each commu-
nity has one nurse-staffed clinic.
Study Procedures
The three island communities were randomly 
assigned, through the drawing of lots, to one of 
three different interventions for scabies control: 
standard care involving the administration of 
permethrin to affected persons and their con-
tacts (standard-care group), mass administration 
of permethrin (permethrin group), or mass ad-
ministration of ivermectin (ivermectin group). 
The study procedures were the same across com-
munities and involved visits at baseline and at 
12 months for all residents and a visit at 3 months 
for a random sample of 20% of each group. Each 
visit took place during a scheduled week.
All residents were eligible to participate. The 
residents were identified with the use of a 2012 
population list provided by the study nurse; they 
were invited by letter to participate and then 
visited by the local district nurse if they were 
present in the community. When the study team 
arrived for the baseline visit, all residents who 
were present at the time were invited to enroll in 
the study. Those who provided consent to par-
ticipate gave basic sociodemographic informa-
tion and a brief medical history. When the study 
team returned for the 12-month visit, all resi-
dents who were present in the community were 
again approached by the study team. The resi-
dents who had enrolled in the study at baseline 
were reexamined and asked about any absences 
from the community since enrollment. The resi-
dents who were present but had not enrolled in 
the study at baseline were invited to enroll. At the 
baseline, 3-month, and 12-month visits, a skin 
examination of consenting participants was per-
formed by the study nurse.
For the groups that underwent mass drug 
administration, data on adverse events were ob-
tained through direct questioning of partici-
pants 7 to 14 days after the drug was adminis-
tered. During the periods before and after the 
drug was administered, we used routinely col-
lected health service data to record the number 
of patients who presented to community clinics 
with any skin condition and the number of 
clinic referrals to major health centers.
In accordance with the Integrated Manage-
ment of Childhood Illness (IMCI) guidelines,13 
scabies was defined as the presence of pruritic 
inflammatory papules with a typical anatomical 
distribution (e.g., on the webs of the fingers, 
hands, wrists, or ankles).26 Examination of the 
breasts and genitals was performed only when 
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requested by participants and in a separate, pri-
vate space. Determination of the severity of 
scabies was based on the number of lesions, in 
categories of mild (≤10), moderate (11 to 49), 
and severe (≥50). Infected scabies was defined as 
scabies plus the presence of pus-filled or crusted 
papules. If crusted (“Norwegian”) scabies was 
suspected, a scraping of the skin was obtained 
for microscopic examination for mites, and a 
photograph was sent to the team’s clinical advi-
sors (the second and last authors). Impetigo was 
defined as the presence of a papular, pustular, 
or ulcerative lesion surrounded by erythema.
 Interventions
 Standard-Care Group
Participants in the standard-care group who had 
scabies at baseline were referred to the local 
clinic for guideline-recommended treatment with 
one dose of topical permethrin cream, with a 
second dose provided after 14 days if symptoms 
persisted. The guidelines also recommended a 
single dose of permethrin for the patient’s con-
tacts.13 We provided permethrin cream to the 
local clinics to ensure that the supply would be 
adequate.
 Permethrin Group
All participants in the permethrin group were 
offered one dose of topical permethrin cream 
followed by a second dose 7 to 14 days later if 
scabies had been observed at baseline. For young-
er children, parents were asked to apply the 
cream under the direct observation of study staff. 
Older children and adults were encouraged to ap-
ply the cream in the clinic but could apply it at 
home. Participants were asked to apply the cream 
from neck to toes and to leave it on for 8 to 24 
hours (or for 4 hours in the case of participants 
<2 months of age). In infants, the cream was also 
applied to the scalp.
 Ivermectin Group
All participants in the ivermectin group were 
offered one dose of oral ivermectin (200 μg per 
kilogram of body weight), which was taken under 
Figure 1. Study Sites in Fiji.
The figure shows the locations of the three island communities that were included in the study. The yellow pin indi­
cates the site of the standard­care group, the red pin the sites of the permethrin group, and the blue pin the sites of 
the ivermectin group.
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the direct observation of study staff. Ivermectin 
was replaced with topical permethrin cream in 
the following participants: children who weighed 
less than 15 kg, women who were pregnant or 
breast-feeding,27 persons with neurologic dis-
ease, and persons taking medications that are 
metabolized by the cytochrome P-450 pathway, 
including warfarin and some anticonvulsant 
agents. For participants who had scabies at base-
line, a second dose of the medication that had 
been provided at baseline was distributed by 
study staff 7 to 14 days after the initial dose was 
administered.
Treatment for crusted scabies consisted of the 
administration of two doses of ivermectin 1 week 
apart and the administration of permethrin 
cream twice a week for 1 month, with follow-up 
at 1, 2, 3, and 12 months.28 All participants with 
crusted or purulent impetigo lesions were re-
ferred to clinics in order to receive antibiotic 
agents, in accordance with Fiji IMCI guidelines.13 
Participants in all groups could present to their 
community clinic at any time and receive stan-
dard care with permethrin.
Study Outcomes
The primary outcome was the change in the 
prevalence of scabies and of impetigo from base-
line to 12 months. Prevalence was calculated at 
baseline and 12 months with the use of data 
from the entire sample of participants at each 
time point.
Safety outcomes were based on adverse events, 
which were classified as serious if they were im-
mediately life threatening, led to hospitalization, 
or resulted in persistent or substantial disability 
or death. We established an independent safety 
committee that consisted of academic physicians, 
including a Fijian representative. Adverse events 
were reviewed by the local study doctor, with 
subsequent referral to the safety committee.
Study Oversight
The trial was approved by the Fijian National Re-
search Ethics Committee and the Royal Children’s 
Hospital Human Research Ethics Committee. 
There was a delay in meeting registration dead-
lines for the study because the investigators ini-
tially were of the understanding that community-
intervention studies of this kind, as opposed to 
individually randomized trials, do not require 
registration. Written informed consent was ob-
tained from all participants. Merck Sharp and 
Dohme (Australia) provided the ivermectin but 
had no other role in the study. The Fiji Ministry 
of Health and Medical Services provided paid 
personnel. The study was designed by the au-
thors. All the authors vouch for the integrity and 
completeness of the data and analyses and for 
the fidelity of the study to the protocol (available 
with the full text of this article at NEJM.org).
Statistical Analysis
We calculated the change in prevalence of sca-
bies and of impetigo in each of the three study 
groups. We calculated both the absolute reduc-
tion (the difference between the prevalence at 
12 months and the prevalence at baseline) and 
the relative reduction (the ratio of the prevalence 
at 12 months to the prevalence at baseline). Con-
fidence intervals for the reductions were calcu-
lated with the use of the variance of the bino-
mial distribution.29 To compare the study groups, 
we calculated the ratio of the prevalence at 
12 months to the prevalence at baseline in each 
group and then tested the null hypothesis that 
these ratios were equal.30 All tests were two-
sided. Among participants who were examined 
at both baseline and 12 months, we calculated 
the rates of the appearance of scabies (the pro-
portion of persons without scabies at baseline 
who had scabies at 12 months) and the disap-
pearance of scabies (the proportion of persons 
with scabies at baseline who did not have scabies 
at 12 months). Safety outcomes were summa-
rized as proportions of participants in each 
group who had adverse events.
Study power and sample size were based on 
estimates from previous research conducted in 
Fiji. We estimated that the prevalence of scabies 
would be 23% at baseline and that the prevalence 
would fall to 5% in the groups that underwent 
mass drug administration6-8 and to 10% in the 
standard-care group.16,31 Assuming an 80% re-
sponse rate in each group and a 20% loss to 
follow-up at 12 months, we estimated that a 
sample of 1920 participants would give the study 
more than 90% power to detect the estimated dif-
ferences at a two-sided significance level of 0.05.
R esult s
Study Population
A total of 2051 persons consented to participate 
in the study (Table 1), representing more than 
85% of the resident population of the three com-
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munities (for details about residents who did not 
participate in the study, see Table S1 in the 
Supplementary Appendix, available at NEJM.org). 
The distributions of age and sex were similar 
across the communities (Table 1); 99.7% of the 
residents in these communities were indigenous 
Fijians (iTaukei). Loss to follow-up at 12 months 
was higher in the standard-care group than in 
the permethrin and ivermectin groups (28.3% vs. 
25.0% and 21.6%, respectively) (Fig. 2, and Table 
S2 in the Supplementary Appendix). At 12 months, 
an additional 246 participants were enrolled, 
with enrollment higher in the standard-care 
group than in the permethrin and ivermectin 
groups (170 persons vs. 50 and 26, respectively).
In the ivermectin group, 623 of the 716 par-
ticipants received ivermectin under the direct 
observation of study staff, and 93 received per-
methrin, in accordance with the exceptions 
specified in the protocol. Of these 93 partici-
pants, 55 were younger than 5 years of age, 27 
were lactating, 8 were pregnant, and 3 had other 
contraindications; the application of permethrin 
was directly observed in 61 of these participants, 
and thus therapy was administered to 96% of 
the ivermectin group under direct observation. 
The 230 participants in this group who had 
scabies at baseline received a second treatment; 
200 received ivermectin and 30 received perme-
thrin, and all the interventions were adminis-
tered under direct observation.
In the permethrin group, 307 of the 532 par-
ticipants (58%) received treatment under direct 
observation, and 181 of the 222 participants 
who had scabies at baseline (82%) received a 
second treatment. No data on the use of perme-
thrin were collected for the standard-care group, 
since all treatment was administered in the 
community clinic.
Prevalence of Scabies and Impetigo
At baseline, the prevalence of scabies was high-
est in the permethrin group, at 41.7% (Table 2). 
Among participants with scabies, the severity at 
baseline was similar across groups; 62% had 
fewer than 10 lesions, and 10% had 50 lesions or 
more. Scabies most commonly involved the hands 
(in 64%), arms (in 38%), feet (in 29%), and legs 
(in 26%). There was one diagnosis of crusted 
scabies in the entire study population, in the 
standard-care group.
At 12 months, the prevalence of scabies had 
declined in all study groups, with the greatest 
decline observed in the ivermectin group. The 
relative reduction in the prevalence of scabies 
was 94% (95% confidence interval [CI], 83 to 
Characteristic Ivermectin Group Permethrin Group Standard-Care Group All Groups
Baseline 
(N = 716)
12 Mo 
(N = 587)
Baseline 
(N = 532)
12 Mo 
(N = 449)
Baseline 
(N = 803)
12 Mo 
(N = 746)
Baseline 
(N = 2051)
12 Mo 
(N = 1782)
Median age (IQR) — yr 24 (8–44) 24 (8–44) 25 (8–47) 26 (8–50) 22 (8–44) 25 (8–45) 24 (8–45) 25 (8–46)
Age — no. (%)
<5 yr 86 (12.0) 71 (12.1) 70 (13.2) 56 (12.5) 101 (12.6) 97 (13.0) 257 (12.5) 224 (12.6)
5–9 yr 134 (18.7) 123 (21.0) 83 (15.6) 80 (17.8) 124 (15.4) 118 (15.8) 341 (16.6) 321 (18.0)
10–14 yr 96 (13.4) 73 (12.4) 60 (11.3) 50 (11.1) 121 (15.1) 88 (11.8) 277 (13.5) 211 (11.8)
15–24 yr 44 (6.1) 25 (4.3) 49 (9.2) 29 (6.5) 75 (9.3) 65 (8.7) 168 (8.2) 119 (6.7)
25–34 yr 106 (14.8) 81 (13.8) 69 (13.0) 56 (12.5) 105 (13.1) 100 (13.4) 280 (13.7) 237 (13.3)
≥35 yr 250 (34.9) 214 (36.4) 201 (37.8) 178 (39.6) 277 (34.5) 278 (37.3) 728 (35.5) 670 (37.6)
Sex — no. (%)
Male 385 (53.8) 309 (52.6) 274 (51.5) 235 (52.3) 405 (50.4) 381 (51.1) 1064 (51.9) 925 (51.9)
Female 331 (46.2) 278 (47.4) 258 (48.5) 214 (47.7) 398 (49.6) 365 (48.9) 987 (48.1) 857 (48.1)
Persons in household — 
median (IQR)
5 (4–7) NA 5 (4–6) NA 5 (4–7) NA 5 (4–7) NA
≥1 Off­island trip in the pre­
vious 12 mo — no. 
of persons (%)
NA 158 (26.9) NA 267 (59.5) NA 232 (31.1) NA 657 (36.9)
*  IQR denotes interquartile range, and NA not applicable.
Table 1. Characteristics of the Participants at Baseline and 12 Months.*
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100) in the ivermectin group, as compared with 
62% (95% CI, 49 to 75) in the permethrin group 
(P<0.001) and 49% (95% CI, 37 to 60) in the 
standard-care group (P<0.001); the difference 
between the permethrin group and the stan-
dard-care group was not significant (P = 0.09). 
The combined relative reduction in the two 
groups that underwent mass drug administra-
tion was 78% (95% CI, 69 to 87).
The reduction in the prevalence of scabies 
was similar when participants who were en-
rolled at 12 months were included in or excluded 
from the analysis (Table S3 in the Supplemen-
tary Appendix). In all groups, there was a reduc-
tion in the prevalence across all age groups and 
both sexes (Tables S4 and S5 in the Supplemen-
tary Appendix), as well as a reduction in the 
proportion of scabies cases that were catego-
rized as severe (≥50 lesions) (Table S6 in the 
Supplementary Appendix).
Figure 2. Enrollment and Follow-up.
The persons enrolled at 12 months were residents who were present at the 12­month visit but had not been present at baseline.
716 (85.3%) Were enrolled
at baseline
839 Residents were eligible
to participate
587 (82.0%) Were included
in 12-mo analysis
939 Residents were eligible
to participate
746 (92.9%) Were included
in 12-mo analysis
Ivermectin Group
625 Residents were eligible
to participate
449 (84.4%) Were included
in 12-mo analysis
Permethrin Group Standard-Care Group
532 (85.1%) Were enrolled
at baseline
803 (85.5%) Were enrolled
at baseline
155 (21.6%) Were
lost to follow-up
at 12 mo
133 (25.0%) Were
lost to follow-up
at 12 mo
227 (28.3%) Were
lost to follow-up
at 12 mo
26 Were enrolled
at 12 mo
50 Were enrolled
at 12 mo
170 Were enrolled
at 12 mo
Study Group Prevalence at Baseline Prevalence at 12 Mo
Absolute Reduction 
in Prevalence
Relative Reduction  
in Prevalence
no./total no. % (95% CI) no./total no. % (95% CI)
percentage points 
(95% CI) % (95% CI)
Ivermectin
Scabies 230/716 32.1 (28.8–35.6) 11/587 1.9 (0.9–3.3) 30.2 (26.6–33.9) 94 (83–100)
Impetigo 176/716 24.6 (21.6–27.9) 47/587 8.0 (6.1–10.5) 16.6 (12.7–20.4) 67 (52–83)
Permethrin
Scabies 222/532 41.7 (37.6–46.0) 71/449 15.8 (12.6–19.5) 25.9 (20.4–31.2) 62 (49–75)
Impetigo 131/532 24.6 (21.2–28.5) 51/449 11.4 (8.8–14.6) 13.3 (8.5–17.9) 54 (35–73)
Standard care
Scabies 294/803 36.6 (33.4–40.0) 140/746 18.8 (16.0–21.8) 17.8 (13.4–21.5) 49 (37–60)
Impetigo 172/803 21.4 (18.7–24.4) 109/746 14.6 (12.3–17.3) 6.8 (3.0–10.6) 32 (14–50)
*  The absolute reduction is the difference between the prevalence at 12 months and the prevalence at baseline, and the relative reduction is 
the ratio of the prevalence at 12 months to the prevalence at baseline. CI denotes confidence interval.
Table 2. Prevalence of Scabies and Impetigo at Baseline and 12 Months.*
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At baseline, the prevalence of impetigo was 
21.4% in the standard-care group and 24.6% in 
the combined groups that underwent mass drug 
administration (Table 2). At 12 months, the 
prevalence of impetigo had declined in all study 
groups, with the greatest decline observed in the 
ivermectin group. The relative reduction in the 
prevalence of impetigo was 67% (95% CI, 52 to 
83) in the ivermectin group, as compared with 
54% (95% CI, 35 to 73) in the permethrin group 
(P = 0.26 for the comparison with the ivermectin 
group) and 32% (95% CI, 14 to 50) in the stan-
dard-care group (P = 0.05 for the comparison 
with the ivermectin group); the difference be-
tween the permethrin group and the standard-
care group was not significant (P = 0.17). The 
combined relative reduction in the two groups 
that underwent mass drug administration was 
62% (95% CI, 49 to 74).
At 12 months, the rate of the appearance 
of scabies was lowest in the ivermectin group 
(1.3%), and the rate of the disappearance of 
scabies was highest in this group (97.3%) (Ta-
ble 3). The prevalence of scabies at 3 months 
was lower than the prevalence at baseline in all 
groups: 13.9% (95% CI, 9.2 to 20.5) in the iver-
mectin group, 22.2% (95% CI, 15.4 to 30.9) in 
the permethrin group, and 10.4% (95% CI, 
6.7 to 16.1) in the standard-care group. The one 
participant with crusted scabies had been clin-
ically cured by the time of the 3-month visit. In 
all the groups, the number of routine clinic 
consultations for skin disease was lower in the 
period after the intervention than in the period 
before the intervention, with 10.6 fewer consul-
tations per 100 baseline population per year in 
the ivermectin group, 7.0 fewer in the perme-
thrin group, and 13.7 fewer in the standard-
care group (Table S7 in the Supplementary Ap-
pendix).
Adverse Events
Adverse events were more common in the iver-
mectin group than in the permethrin group (with 
15.6% having an event and 205 events in 112 
participants vs. 6.8% having an event and 46 
events in 36 participants) (Tables S8 and S9 in 
the Supplementary Appendix). No adverse event 
was serious or persisted for more than 7 days. 
Itching was the most common event (affecting 
5.3% and 3.6% of participants in the ivermectin 
and permethrin groups, respectively), followed by 
headache (affecting 3.8% and 0.9%, respectively).
Discussion
In this comparative trial, we found significant 
reductions in the prevalence of both scabies and 
impetigo from baseline to 1 year in all groups, 
with by far the largest reduction in the ivermec-
tin group. Adverse events were more common in 
the ivermectin group, but all events were mild 
and resolved quickly.
Mass drug administration shows promise as 
an important control strategy in countries in 
which scabies is endemic. Previous single-group 
studies of the mass administration of perme-
thrin and of ivermectin have shown reductions 
in disease prevalence6-8,20,32 but have not deter-
mined whether this strategy is superior to an 
effective application of standard care.
In our study, the prevalence of scabies in the 
groups that underwent mass drug administra-
tion had declined by 3 months and declined 
further by 12 months; this finding was some-
what contrary to our expectation. A proportion 
Study Group Disappearance of Scabies Appearance of Scabies
Scabies Present 
at Baseline
Scabies Absent  
at 12 Mo
Rate of 
Disappearance
Scabies Absent  
at Baseline
Scabies Present 
at 12 Mo
Rate of 
Appearance
no. of patients % (95% CI) no. of patients % (95% CI)
Ivermectin 187 182 97.3 (93.9–99.1) 374 5 1.3 (0.4–3.1)
Permethrin 174 130 74.7 (67.6–81.0) 225 18 8.0 (4.8–12.3)
Standard care 218 161 73.9 (67.5–79.6) 358 55 15.4 (11.8–19.5)
Table 3. Rates of Disappearance and Appearance of Scabies among Participants Who Were Examined at Both Baseline 
and 12 Months.
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of the scabies cases detected at 3 months may 
have represented postscabietic inflammatory 
nodules, which can persist after successful treat-
ment.26,33
The relative reduction in the prevalence of 
scabies from baseline to 12 months was signifi-
cantly greater in the ivermectin group than in 
the permethrin group (94% vs. 62%). During 
mass administration, any therapeutic advantage 
of permethrin34 may be outweighed by poor ad-
herence to the topical agent.17 Administration of 
treatment was directly observed much more fre-
quently in the ivermectin group than in the 
permethrin group (96% vs. 58%). The effect of 
adherence in the ivermectin group may have been 
enhanced by the second dose for participants 
with clinical scabies at baseline, since ivermec-
tin is not effective against unhatched eggs.35
Adverse-event profiles were consistent with 
those in previous studies.36 Itching was the most 
common event and was probably caused by an 
inflammatory response to dead mite antigens. 
The extensive mass administration of ivermectin 
in Africa and Latin America24,37 has raised no 
safety concerns, except for a contraindication to 
the drug among persons at risk for Loa loa fila-
riasis.38 In the absence of data on safety in young 
children and pregnant women, caution dictates 
that the drug remain contraindicated in these 
two groups.
The considerable decline in the prevalence of 
scabies in the standard-care group may have oc-
curred because the trial introduced a higher 
level of care than had been routinely available, 
including ensuring the availability of permethrin 
and generating greater awareness about treat-
ment for contacts.
This study has several limitations. A true 
cluster-randomized trial would have required 
multiple communities to be included in each 
group, but this trial design was beyond the re-
sources available to us. We targeted a very sub-
stantial level of effect to minimize the possibil-
ity that any finding would be interpreted as 
being a result of confounding. There were never-
theless differences among the three trial com-
munities, with respect to population movement 
and isolation from the main island of Viti Levu 
(Fig. 1). The standard-care group had access to 
private boats to the main island, and the per-
methrin group had easier access to the main-
land by ferry than did the ivermectin group. 
These differences were reflected in the reported 
movements of study participants and may have 
contributed to a greater potential for reinfesta-
tion in the standard-care and permethrin groups 
than in the ivermectin group. Finally, the high 
prevalences of scabies and impetigo at baseline 
were consistent with findings from earlier sur-
veys in the Pacific Islands.39 We used validated 
diagnostic criteria13 but not dermatoscopy, since 
this type of examination was not practical to 
perform and has poor sensitivity.40,41 The study 
nurse who performed all skin examinations 
had worked at the only dermatology hospital in 
Fiji for more than 20 years and had had particu-
lar experience in the detection of scabies and 
impetigo. We did not systematically examine 
breasts and genitals, which are regions with a 
predilection for infestation,19,42 but any result-
ing underestimation is unlikely to have differed 
among the three groups.
These data support the mass administration 
of ivermectin for scabies control. Although sca-
bies resistance has been reported very infre-
quently, it could occur.43,44 We provided a second 
dose for participants who had scabies at base-
line, but a simpler strategy for mass administra-
tion on a larger scale would be to provide two 
directly observed doses 7 to 14 days apart, re-
gardless of whether clinical scabies is present. 
There is an opportunity to evaluate the effect of 
existing ivermectin-based programs for oncho-
cerciasis and lymphatic filariasis on scabies and 
other ivermectin-susceptible parasites. In gener-
al, approaches to mass drug administration may 
yield better results if they are integrated across 
diseases in a way that is acceptable to individual 
persons and communities.
SHIFT fills an important gap in evidence for 
scabies control, but effectiveness must now be 
evaluated beyond island settings and in larger 
populations. Key issues will include the number 
of cycles needed; the model of delivery; the 
mechanism for evaluation of efficacy, cost effec-
tiveness, and acceptability; and the effect of sca-
bies and impetigo control on the severe down-
stream complications of these skin conditions.45
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